Research · Sep 3, 2026
[HOLX] Hologic Thesis 2026: Diagnostics Recovery Tests Post-COVID Normalization
Hologic Inc. FY2025 revenue ~$4.0-4.2B (+0-2% post-COVID molecular diagnostics normalization) with adj. EPS ~$4.10-4.30 reflecting continued post-COVID molecular diagnostics demand normalization (selected 2020-2022 COVID-19 testing demand surge fully unwound) + selected Breast Health stable + selected Surgical growth + selected operational discipline. Global women's health diagnostics + medical device company; founded 1985 by S. David Ellenbogen + Jay Stein in Bedford Massachusetts (originally bone densitometry company). Headquartered in Marlborough Massachusetts. 4 segments: Diagnostics ~36% ($1.5B — molecular diagnostics Panther platform + Aptima HPV + selected respiratory + STI tests + cytology ThinPrep + perinatal) + Breast Health ~32% ($1.3B — mammography Genius 3D selected market leadership + Selenia + biopsy + Faxitron specimen radiography; ~7,000+ US imaging center installed base) + Surgical ~14% ($0.6B — NovaSure uterine ablation + MyoSure uterine fibroid removal selected niche leadership) + Skeletal ~3% ($0.1B — bone densitometry legacy original Hologic business). CEO Steve MacMillan since December 2013 (long-tenured ~12-year tenure; ex-Stryker Group President; ~25-year medical device executive career). MacMillan tenure executed continued operational excellence + Cynosure $205M divestiture 2017 + Faxitron + selected smaller acquisitions + 2020-2022 COVID molecular testing surge management (~$2-3B peak COVID-related revenue) + post-COVID normalization. Capital return: no dividend + buybacks $1-1.5B (aggressive ~3-5%/yr share count reduction; share count 250M FY2022 → 225M FY2025E ~10% reduction); net debt $0.5-1B (modest); Baa3/BBB- investment grade. FY2026 thesis: Diagnostics post-COVID normalization completion + Breast Health stability + Surgical growth + capital return. Risks: post-COVID demand normalization, breast health competitive intensity, hospital capex.